The article "Prospects and Challenges of CAR-T Cell Therapy Combined with ICIs" by Yufan Lv et al. discusses the potential and limitations of combining CAR-T cell therapy with immune checkpoint inhibitors (ICIs) to treat solid tumors. The authors highlight the challenges of CAR-T therapy in solid tumors, including antigenic heterogeneity, physical barriers, and a suppressive tumor microenvironment (TME). They also explore the mechanisms of CAR-T cell exhaustion and the role of ICIs in enhancing CAR-T function. The review outlines various strategies for clinical application, such as exogenous ICIs combined with CAR-T therapy, autocrine production of ICIs by CAR-T cells, and multi-target blockade of immune checkpoints. Additionally, it discusses new delivery systems like CRISPR-Cas9 and other novel immune combination therapies. The authors conclude that while CAR-T therapy combined with ICIs shows promise, more research and clinical trials are needed to fully realize its potential in treating solid tumors.The article "Prospects and Challenges of CAR-T Cell Therapy Combined with ICIs" by Yufan Lv et al. discusses the potential and limitations of combining CAR-T cell therapy with immune checkpoint inhibitors (ICIs) to treat solid tumors. The authors highlight the challenges of CAR-T therapy in solid tumors, including antigenic heterogeneity, physical barriers, and a suppressive tumor microenvironment (TME). They also explore the mechanisms of CAR-T cell exhaustion and the role of ICIs in enhancing CAR-T function. The review outlines various strategies for clinical application, such as exogenous ICIs combined with CAR-T therapy, autocrine production of ICIs by CAR-T cells, and multi-target blockade of immune checkpoints. Additionally, it discusses new delivery systems like CRISPR-Cas9 and other novel immune combination therapies. The authors conclude that while CAR-T therapy combined with ICIs shows promise, more research and clinical trials are needed to fully realize its potential in treating solid tumors.